Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2014 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year
Filters applied: . Clear all
Page 1
[Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
Petelina TI, Gapon LI, Bakhmatova IuA, Zhevagina IA. Petelina TI, et al. Ter Arkh. 2005;77(8):19-23. Ter Arkh. 2005. PMID: 16206600 Clinical Trial. Russian.
AIM: To compare hypotensive and antiischemic efficacy of enalapril combination with trimetazidine or placebo, effects on plasmic lipid spectrum and membrane-cell parameters of erythrocytes and platelets in hypertensive patients with ischemic heart disease
AIM: To compare hypotensive and antiischemic efficacy of enalapril combination with trimetazidine or placebo, effects on plasmic lipi …
Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
Ussher JR, Fillmore N, Keung W, Mori J, Beker DL, Wagg CS, Jaswal JS, Lopaschuk GD. Ussher JR, et al. Can J Cardiol. 2014 Aug;30(8):940-4. doi: 10.1016/j.cjca.2014.04.023. Epub 2014 Apr 29. Can J Cardiol. 2014. PMID: 25064584
Obesity is a significant risk factor for the development of cardiovascular disease. Inhibiting fatty acid oxidation has emerged as a novel approach for the treatment of ischemic heart disease. ...A 3-week treatment with the 3-KAT inhibitor tr
Obesity is a significant risk factor for the development of cardiovascular disease. Inhibiting fatty acid oxidation has emerge
Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
Ussher JR, Keung W, Fillmore N, Koves TR, Mori J, Zhang L, Lopaschuk DG, Ilkayeva OR, Wagg CS, Jaswal JS, Muoio DM, Lopaschuk GD. Ussher JR, et al. J Pharmacol Exp Ther. 2014 Jun;349(3):487-96. doi: 10.1124/jpet.114.214197. Epub 2014 Apr 3. J Pharmacol Exp Ther. 2014. PMID: 24700885 Free PMC article.
There is a growing need to understand the underlying mechanisms involved in the progression of cardiovascular disease during obesity and diabetes. Although inhibition of fatty acid oxidation has been proposed as a novel approach to treat ischemic heart
There is a growing need to understand the underlying mechanisms involved in the progression of cardiovascular disease during obesi
[Limited application of prevention measures in patients with diabetes mellitus type 2 and coronary artery disease in Spain. DIETRIC study].
Rodríguez Padial L, Maicas Bellido C, Alcalá López J, Velázquez Martín M, Gil Polo B. Rodríguez Padial L, et al. Rev Clin Esp. 2005 Jan;205(1):14-8. doi: 10.1157/13070753. Rev Clin Esp. 2005. PMID: 15718012 Spanish.
The objective of this study is to define the control degree of cardiovascular risk factors in patients with diabetes and coronary artery disease. METHODS: In DIETRIC study 628 patients with diabetes type 2 and coronary artery disease have …
The objective of this study is to define the control degree of cardiovascular risk factors in patients with diabetes and coronary
Feedback